Skip to main content
Top
Published in: The European Journal of Health Economics 6/2016

Open Access 01-07-2016 | Original Paper

Economic evaluation in chronic pain: a systematic review and de novo flexible economic model

Authors: W. Sullivan, M. Hirst, S. Beard, D. Gladwell, F. Fagnani, J. López Bastida, C. Phillips, W. C. N. Dunlop

Published in: The European Journal of Health Economics | Issue 6/2016

Login to get access

Abstract

There is unmet need in patients suffering from chronic pain, yet innovation may be impeded by the difficulty of justifying economic value in a field beset by data limitations and methodological variability. A systematic review was conducted to identify and summarise the key areas of variability and limitations in modelling approaches in the economic evaluation of treatments for chronic pain. The results of the literature review were then used to support the development of a fully flexible open-source economic model structure, designed to test structural and data assumptions and act as a reference for future modelling practice. The key model design themes identified from the systematic review included: time horizon; titration and stabilisation; number of treatment lines; choice/ordering of treatment; and the impact of parameter uncertainty (given reliance on expert opinion). Exploratory analyses using the model to compare a hypothetical novel therapy versus morphine as first-line treatments showed cost-effectiveness results to be sensitive to structural and data assumptions. Assumptions about the treatment pathway and choice of time horizon were key model drivers. Our results suggest structural model design and data assumptions may have driven previous cost-effectiveness results and ultimately decisions based on economic value. We therefore conclude that it is vital that future economic models in chronic pain are designed to be fully transparent and hope our open-source code is useful in order to aspire to a common approach to modelling pain that includes robust sensitivity analyses to test structural and parameter uncertainty.
Appendix
Available only for authorised users
Footnotes
1
The different treatment pathway for chronic neuropathic pain compared to other chronic pain means that it falls outside of the scope of this study.
 
Literature
1.
go back to reference Merskey, H., Bogduk, N: Classification of chronic pain. IASP task force on taxonomy. International Association for the Study of Pain Press, Seattle, WA (1994). http://www.iasp-pain.org Merskey, H., Bogduk, N: Classification of chronic pain. IASP task force on taxonomy. International Association for the Study of Pain Press, Seattle, WA (1994). http://​www.​iasp-pain.​org
2.
go back to reference Merchant, S., et al.: Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. Clin. Ther. 35(5), 659–672 (2013)CrossRefPubMed Merchant, S., et al.: Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. Clin. Ther. 35(5), 659–672 (2013)CrossRefPubMed
4.
go back to reference Breivik, H., Eisenberg, E., Tony, O.: The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC public health 13(1), 1229 (2013)CrossRefPubMedPubMedCentral Breivik, H., Eisenberg, E., Tony, O.: The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC public health 13(1), 1229 (2013)CrossRefPubMedPubMedCentral
5.
go back to reference Neil, N., et al.: Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States. J. Med. Econ. 16(2), 307–317 (2013)CrossRefPubMed Neil, N., et al.: Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States. J. Med. Econ. 16(2), 307–317 (2013)CrossRefPubMed
6.
go back to reference Neighbors, D.M., et al.: Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J. Pain Symp. Manag. 21(2), 129–143 (2001)CrossRef Neighbors, D.M., et al.: Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J. Pain Symp. Manag. 21(2), 129–143 (2001)CrossRef
7.
go back to reference Frei, A., et al.: A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J. Pain Palliat. Care Pharmacother. 17(2), 5–26 (2003)CrossRefPubMed Frei, A., et al.: A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J. Pain Palliat. Care Pharmacother. 17(2), 5–26 (2003)CrossRefPubMed
8.
go back to reference Ericson, L., et al.: Opioid rotation in patients initiated on oxycodone or morphine: a register study. J Pain Res 6, 379–386 (2013)PubMedPubMedCentral Ericson, L., et al.: Opioid rotation in patients initiated on oxycodone or morphine: a register study. J Pain Res 6, 379–386 (2013)PubMedPubMedCentral
9.
go back to reference Berger, A., et al.: Therapy switching in patients receiving long-acting opioids. Ann. Pharmacother. 38(3), 389–395 (2004)CrossRefPubMed Berger, A., et al.: Therapy switching in patients receiving long-acting opioids. Ann. Pharmacother. 38(3), 389–395 (2004)CrossRefPubMed
11.
go back to reference Lehmann, K., et al.: Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur. J. Health Econ. 3(2), 111–119 (2002)CrossRefPubMed Lehmann, K., et al.: Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur. J. Health Econ. 3(2), 111–119 (2002)CrossRefPubMed
12.
go back to reference Greiner, W., et al.: Economic evaluation of durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur. J. Health Econ. 7(4), 290–296 (2006)CrossRefPubMed Greiner, W., et al.: Economic evaluation of durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur. J. Health Econ. 7(4), 290–296 (2006)CrossRefPubMed
13.
go back to reference Ikenberg, R., et al.: Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J. Med. Econ. 15(4), 724–736 (2012)CrossRefPubMed Ikenberg, R., et al.: Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J. Med. Econ. 15(4), 724–736 (2012)CrossRefPubMed
14.
go back to reference Obradovic, M., et al.: Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin. Ther. 34(4), 926–943 (2012)CrossRefPubMed Obradovic, M., et al.: Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin. Ther. 34(4), 926–943 (2012)CrossRefPubMed
15.
go back to reference Hass, B., et al.: Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach. Eur. J. Health Econ. 10(3), 309–321 (2009)CrossRefPubMed Hass, B., et al.: Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach. Eur. J. Health Econ. 10(3), 309–321 (2009)CrossRefPubMed
16.
go back to reference Hauber, A.B., et al.: Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J. Opioid Manag. 7(4), 287–296 (2011)CrossRefPubMed Hauber, A.B., et al.: Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J. Opioid Manag. 7(4), 287–296 (2011)CrossRefPubMed
17.
go back to reference Dunlop, W., et al.: Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J. Med. Econ. 15, 564–575 (2012)CrossRefPubMed Dunlop, W., et al.: Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J. Med. Econ. 15, 564–575 (2012)CrossRefPubMed
18.
go back to reference Coluzzi, F., Ruggeri, M.: Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr. Med. Res. Opin. 30, 1139–1151 (2014)CrossRefPubMed Coluzzi, F., Ruggeri, M.: Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr. Med. Res. Opin. 30, 1139–1151 (2014)CrossRefPubMed
20.
go back to reference Wickham, H.: ggplot2: elegant graphics for data analysis. Springer, New York (2009)CrossRef Wickham, H.: ggplot2: elegant graphics for data analysis. Springer, New York (2009)CrossRef
23.
go back to reference Lange, B., et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv. Ther. 27(6), 381–399 (2010)CrossRefPubMed Lange, B., et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv. Ther. 27(6), 381–399 (2010)CrossRefPubMed
24.
go back to reference Simpson, K., et al.: Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr. Med. Res. Opin. 24(12), 3503–3512 (2008)CrossRefPubMed Simpson, K., et al.: Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr. Med. Res. Opin. 24(12), 3503–3512 (2008)CrossRefPubMed
25.
go back to reference Goossens, M.E., et al.: Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 80(1), 365–375 (1999)CrossRefPubMed Goossens, M.E., et al.: Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 80(1), 365–375 (1999)CrossRefPubMed
26.
go back to reference Bala, M.V., et al.: Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J. Clin. Epidemiol. 51(8), 667–676 (1998)CrossRefPubMed Bala, M.V., et al.: Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J. Clin. Epidemiol. 51(8), 667–676 (1998)CrossRefPubMed
29.
go back to reference Gordon, J., et al.: A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J. Med. Econ. 15(2), 207–218 (2012)CrossRefPubMed Gordon, J., et al.: A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J. Med. Econ. 15(2), 207–218 (2012)CrossRefPubMed
30.
go back to reference Sullivan, W., Payne, K.: The appropriate elicitation of expert opinion in economic models. PharmacoEconomics 29(6), 455–459 (2011)CrossRefPubMed Sullivan, W., Payne, K.: The appropriate elicitation of expert opinion in economic models. PharmacoEconomics 29(6), 455–459 (2011)CrossRefPubMed
Metadata
Title
Economic evaluation in chronic pain: a systematic review and de novo flexible economic model
Authors
W. Sullivan
M. Hirst
S. Beard
D. Gladwell
F. Fagnani
J. López Bastida
C. Phillips
W. C. N. Dunlop
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 6/2016
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-015-0720-y

Other articles of this Issue 6/2016

The European Journal of Health Economics 6/2016 Go to the issue